Literature DB >> 10628338

Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells.

S I Kumeda1, A Deguchi, M Toi, S Omura, K Umezawa.   

Abstract

In search for angiogenesis inhibitors, we tested protease and proteasome inhibitors for the induction of G1 arrest and selective inhibition of growth of human umbilical vein endothelial cells (HUVECs). Serine protease-, cysteine protease-, aspartate protease-, and aminopeptidase-inhibitors did not inhibit bFGF/FBS-induced S-phase induction in HUVECs, but a proteasome inhibitor, lactacystin did inhibit it reversibly. Lactacystin increased the cellular level of p53 and cdk2-associated p21WAF1/CIP1 leading to cdk2 inactivation. In addition to the angiogenesis inhibitor TNP-470, lactacystin also inhibited the growth of HUVECs selectively at about a 20 times lower concentration than that of other human cell lines, including normal fibroblasts and carcinoma cells. Lactacystin induced p53-dependent p21WAF1/CIP1 expression at lower concentrations in HUVECs than in other cells. These cellular effects were also observed with a tripeptide-type proteasome inhibitor, N-Ac-Leu-Leu-norleucinal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628338

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Proteasomal degradation of human peptidyl prolyl isomerase pin1-pointing phospho Bcl2 toward dephosphorylation.

Authors:  Aruna Basu; Madhusudan Das; Suparna Qanungo; Xue-Jun Fan; Garrett DuBois; Subrata Haldar
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

2.  Inhibition of ubiquitin proteasome function suppresses proliferation of pulmonary artery smooth muscle cells.

Authors:  Manxiang Li; Xilin Dong; Yuan Liu; Xiuzhen Sun; Zongfang Li; Jiyin He
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-08-19       Impact factor: 3.000

3.  Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1.

Authors:  Y Zhang; E C Griffith; J Sage; T Jacks; J O Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

4.  Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.

Authors:  H G Hotz; H A Reber; B Hotz; P C Sanghavi; T Yu; T Foitzik; H J Buhr; O J Hines
Journal:  J Gastrointest Surg       Date:  2001 Mar-Apr       Impact factor: 3.452

5.  Effects of TNP-470 on proliferation and apoptosis in human colon cancer xenografts in nude mice.

Authors:  Zong-Hai Huang; Ying-Fang Fan; Hu Xia; Hao-Miao Feng; Fu-Xiang Tang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

6.  Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.

Authors:  Ivana Zavrski; Cord Naujokat; Kathrin Niemöller; Christian Jakob; Ulrike Heider; Corinna Langelotz; Claudia Fleissner; Jan Eucker; Kurt Possinger; Orhan Sezer
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-08       Impact factor: 4.553

7.  Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes.

Authors:  Honglin Luo; Jingchun Zhang; Caroline Cheung; Agripina Suarez; Bruce M McManus; Decheng Yang
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

8.  Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.

Authors:  Carsten Berges; Heinrich Haberstock; Dominik Fuchs; Marion Miltz; Mahmoud Sadeghi; Gerhard Opelz; Volker Daniel; Cord Naujokat
Journal:  Immunology       Date:  2008-01-23       Impact factor: 7.397

9.  The proteasome inhibitor lactacystin attenuates growth and migration of vascular smooth muscle cells and limits the response to arterial injury.

Authors:  Kurt G Barringhaus; Martin E Matsumura
Journal:  Exp Clin Cardiol       Date:  2007

10.  Phosphorylation of the 19S regulatory particle ATPase subunit, Rpt6, modifies susceptibility to proteotoxic stress and protein aggregation.

Authors:  Esther Magdalena Marquez-Lona; Ana Lilia Torres-Machorro; Frankie R Gonzales; Lorraine Pillus; Gentry N Patrick
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.